Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3201
SES AI
SES
$187M
| $159K | ﹤0.01% |
86,900
-61,195
| -41% | -$132K |
|
|
AEVA
3202
Aeva Technologies
AEVA
$1.73B
| $157K | ﹤0.01% |
41,420
+36,880
| +812% | +$118K |
|
3203
CuriosityStream
CURI
$159M
| $157K | ﹤0.01% |
290,100
+17,200
| +6% | +$10.4K |
|
3204
Superior Group of Companies
SGC
$225M
| $157K | ﹤0.01% |
11,600
-35,100
| -75% | -$367K |
|
|
ENFN
3205
DELISTED
Enfusion, Inc.
ENFN
| $155K | ﹤0.01% |
+16,000
| New | +$149K |
|
|
GGE
3206
DELISTED
Green Giant Inc. Common Stock
GGE
| $155K | ﹤0.01% |
+2,970,340
| New | +$2.15M |
|
3207
Cogent Biosciences
COGT
$7.14B
| $154K | ﹤0.01% |
+26,268
| New | +$201K |
|
|
HOOK
3208
DELISTED
HOOKIPA Pharma
HOOK
| $153K | ﹤0.01% |
18,865
-36,699
| -66% | -$202K |
|
|
NCNA
3209
NuCana
NCNA
$5.66M
| $153K | ﹤0.01% |
104
+33
| +46% | +$75.6K |
|
3210
Zymeworks
ZYME
$1.7B
| $153K | ﹤0.01% |
14,700
-1,158
| -7% | -$9.23K |
|
3211
The Beachbody Company
BODI
$72.3M
| $153K | ﹤0.01% |
18,464
+4,846
| +36% | +$51.8K |
|
3212
Direxion Daily Dow Jones Internet Bear 3X ETF
WEBS
$6.93M
| $152K | ﹤0.01% |
+1,780
| New | +$221K |
|
3213
DarioHealth
DRIO
$75.5M
| $151K | ﹤0.01% |
4,400
+545
| +14% | +$19.4K |
|
|
AHG
3214
Akso Health Group
AHG
$1.13B
| $149K | ﹤0.01% |
201,898
+2,500
| +1% | +$2.69K |
|
3215
Traws Pharma
TRAW
$8.21M
| $148K | ﹤0.01% |
7,954
+606
| +8% | +$10.3K |
|
3216
Daxor
DXR
$61.2M
| $147K | ﹤0.01% |
15,321
-500
| -3% | -$4.14K |
|
|
TAOX
3217
Tao Synergies Inc
TAOX
$25.7M
| $147K | ﹤0.01% |
21,635
+20,703
| +2,221% | +$150K |
|
|
EAR
3218
DELISTED
Eargo, Inc. Common Stock
EAR
| $147K | ﹤0.01% |
56,580
+8,600
| +18% | +$20.3K |
|
|
AMBR
3219
Amber International Holding Ltd
AMBR
$128M
| $146K | ﹤0.01% |
38,143
| – | – |
|
3220
Rani Therapeutics
RANI
$87.8M
| $145K | ﹤0.01% |
43,700
-7,300
| -14% | -$16.9K |
|
|
HARP
3221
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $145K | ﹤0.01% |
12,756
-12,100
| -49% | -$95.1K |
|
3222
American Express Global Business Travel
GBTG
$4.93B
| $144K | ﹤0.01% |
+22,400
| New | +$128K |
|
|
THRD
3223
DELISTED
Third Harmonic Bio
THRD
| $143K | ﹤0.01% |
+13,000
| New | +$103K |
|
|
ZENV
3224
DELISTED
Zenvia
ZENV
| $143K | ﹤0.01% |
121,200
+31,000
| +34% | +$35.3K |
|
3225
Ocugen
OCGN
$420M
| $142K | ﹤0.01% |
246,173
-674,978
| -73% | -$271K |
|
Similar funds
Renaissance Technologies's Q4 2023 Portfolio in Review
As of Q4 2023, Renaissance Technologies held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Renaissance Technologies added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Renaissance Technologies's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Renaissance Technologies fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Renaissance Technologies's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Renaissance Technologies opened 702 new positions and closed 633 in Q4 2023.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.